NasdaqCM - Nasdaq Real Time Price USD

NeuBase Therapeutics, Inc. (NBSE)

0.4338 -0.0082 (-1.86%)
As of 10:24 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Todd P. Branning Interim CEO, CFO & Secretary 427.44k -- 1970
Dr. Dietrich A. Stephan Ph.D. Founder, President & Director 836.58k -- 1970

NeuBase Therapeutics, Inc.

350 Technology Drive
Suite 421
Pittsburgh, PA 15219
United States
412 763 3350 https://www.neubasetherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
37

Description

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Corporate Governance

NeuBase Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 26, 2024 - Apr 28, 2024
NeuBase Therapeutics, Inc. Earnings Call

Related Tickers

LIPO Lipella Pharmaceuticals Inc.
0.7200
+2.26%
 
XCUR Exicure, Inc.
0.5126
+0.91%
 
CMRA Comera Life Sciences Holdings, Inc.
0.0361
0.00%
 
DBVT DBV Technologies S.A.
0.6711
-1.67%
 
CMMB Chemomab Therapeutics Ltd.
0.6300
-4.40%
 
FBRX Forte Biosciences, Inc.
0.7399
+3.22%
 
KTTA Pasithea Therapeutics Corp.
7.24
0.00%
 
PRTG Portage Biotech Inc.
0.2351
-6.96%
 
HSTC HST Global, Inc.
0.9400
0.00%
 
DRMA Dermata Therapeutics, Inc.
0.3583
+0.65%